Limited systemic sclerosis (lSSc) (or SSc sine scleroderma) is a subset of systemic sclerosis (SSc) characterized by organ involvement in the absence of fibrosis of the skin.
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 11, 2026
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning limited systemic sclerosis
Updated Feb 18, 2026
A systematic review protocol has been established to investigate cytometry-based blood immune cell markers and their association with clinical outcomes in systemic sclerosis. This research aims to enhance understanding of immune responses in this rare disease.
Recent research explores the management of pulmonary arterial hypertension in systemic sclerosis, highlighting advancements from traditional therapies to innovative approaches. This study provides insights into evolving treatment strategies for this complex condition.
New research emphasizes the importance of human genetic association studies in advancing drug development for systemic sclerosis. This approach aims to enhance understanding and treatment options for this complex disease.
Recent research indicates that targeting the PD-1 pathway may reduce inflammation and fibrosis in systemic sclerosis. This discovery could lead to new therapeutic strategies for managing this challenging condition.
A recent retrospective cohort study investigates the impact of hydroxychloroquine on mortality and cardiovascular outcomes in systemic sclerosis. The findings contribute to understanding treatment efficacy in this rare disease.